|
covid-19 |
37 |
|
influenza |
21 |
|
sars-cov-2 |
21 |
|
epidemiology |
19 |
|
disease burden |
16 |
|
influenza a(h7n9) |
14 |
|
severity |
14 |
|
impact |
13 |
|
transmission |
13 |
|
hospitalization |
12 |
|
public health |
12 |
|
reproduction number |
12 |
|
surveillance |
12 |
|
transmissibility |
12 |
|
death |
11 |
|
human influenza |
11 |
|
antimicrobial resistance |
10 |
|
coronavirus disease 2019 |
10 |
|
disparities |
10 |
|
intervention |
10 |
|
socioeconomic |
10 |
|
work from home |
10 |
|
communicable disease control - methods |
9 |
|
excess mortality |
9 |
|
mass testing |
9 |
|
transmission dynamics |
9 |
|
age distribution |
8 |
|
behavior change |
8 |
|
china |
8 |
|
coronavirus |
8 |
|
coughing |
8 |
|
disease predisposition |
8 |
|
disease surveillance |
8 |
|
humidity |
8 |
|
meta-analysis |
8 |
|
pandemic |
8 |
|
seasonality |
8 |
|
2019 novel coronavirus disease |
7 |
|
attitudes |
7 |
|
avian influenza a(h7n9) |
7 |
|
carbapenemase-producing enterobacteriaceae |
7 |
|
carriage |
7 |
|
clinical epidemiology |
7 |
|
cluster |
7 |
|
communicable diseases, emerging - prevention and control - transmission |
7 |
|
coronavirus disease |
7 |
|
enterovirus |
7 |
|
face masks |
7 |
|
importation |
7 |
|
incubation period |
7 |
|
influenza a virus |
7 |
|
influenza a virus, h7n9 subtype |
7 |
|
influenza a(h5n1) |
7 |
|
influenza in birds - prevention and control - transmission |
7 |
|
influenza, human - prevention and control - transmission |
7 |
|
live poultry markets |
7 |
|
nested case-control study |
7 |
|
risk factor |
7 |
|
systematic review |
7 |
|
united kingdom |
7 |
|
variant |
7 |
|
adolescent |
6 |
|
adult |
6 |
|
aged |
6 |
|
antimicrobial stewardship |
6 |
|
avian influenza a (h7n9) |
6 |
|
case clusters |
6 |
|
children |
6 |
|
clinical diagnosis |
6 |
|
clinical prediction rule |
6 |
|
control |
6 |
|
disease outbreaks |
6 |
|
disease severity |
6 |
|
disease transmission |
6 |
|
epidemiological monitoring |
6 |
|
generation time |
6 |
|
h7n9 subtype |
6 |
|
high-rise buildings |
6 |
|
hospital emergency setting |
6 |
|
imported case |
6 |
|
infectious disease outbreak |
6 |
|
influenza a |
6 |
|
influenza in birds - mortality - transmission |
6 |
|
influenza virus |
6 |
|
influenza, human - mortality |
6 |
|
interventions |
6 |
|
latent class analysis |
6 |
|
line list |
6 |
|
omicron variants |
6 |
|
pandemic preparedness |
6 |
|
pandemic responses |
6 |
|
prediction |
6 |
|
prescribing |
6 |
|
protective behaviors |
6 |
|
quarantine |
6 |
|
respiration, artificial - statistics and numerical data |
6 |
|
respiratory tract infections |
6 |
|
risk perception |
6 |
|
seriousness |
6 |
|
seroprevalence |
6 |
|
travel |
6 |
|
tuberculosis - epidemiology |
6 |
|
vaccination |
6 |
|
viral loads |
6 |
|
a(h7n9) |
5 |
|
basic reproduction number |
5 |
|
children. |
5 |
|
cohort |
5 |
|
controlled study |
5 |
|
credible interval |
5 |
|
disease control |
5 |
|
dispersion parameter |
5 |
|
epidemic |
5 |
|
h1n1pdm09 |
5 |
|
h5n1 |
5 |
|
h5n6 |
5 |
|
h7n9 |
5 |
|
hand-foot-and-mouth disease (hfmd) |
5 |
|
influenza b |
5 |
|
isolation delays |
5 |
|
mortality |
5 |
|
protective behaviours |
5 |
|
regression analysis |
5 |
|
respiratory syncytial virus (rsv) |
5 |
|
serial intervals |
5 |
|
seroepidemiology |
5 |
|
severe outcomes |
5 |
|
social norms |
5 |
|
superspreading |
5 |
|
susceptibility |
5 |
|
systematic review and meta-analysis |
5 |
|
trajectory |
5 |
|
vaccination policy assessment |
5 |
|
vaccine hesitancy |
5 |
|
vaccine passport |
5 |
|
vaccine uptake |
5 |
|
antibiotic resistance genes |
4 |
|
biocide resistance genes |
4 |
|
cause of death |
4 |
|
cities - epidemiology |
4 |
|
cost-effectiveness analysis |
4 |
|
epidemiologic methods |
4 |
|
face mask |
4 |
|
gut microbiome |
4 |
|
hand sanitizer |
4 |
|
health policy |
4 |
|
hong kong - epidemiology |
4 |
|
imported cases |
4 |
|
in-hospital mortality |
4 |
|
incidence |
4 |
|
influenza a virus, h1n1 subtype - isolation and purification |
4 |
|
influenza vaccines - administration and dosage - immunology |
4 |
|
influenza, human - epidemiology - prevention and control - transmission - virology |
4 |
|
influenza, human - epidemiology - prevention and control - virology |
4 |
|
influenza‐like illness |
4 |
|
life expectancy |
4 |
|
life table |
4 |
|
mass screening - methods |
4 |
|
obesity |
4 |
|
older adults |
4 |
|
orthomyxoviridae - immunology - isolation and purification |
4 |
|
out-of-hospital mortality |
4 |
|
pandemics |
4 |
|
parametric bootstrap |
4 |
|
pregnancy |
4 |
|
reproductive number |
4 |
|
respiratory mortality |
4 |
|
seasonal |
4 |
|
subsidy |
4 |
|
systematic reviews |
4 |
|
target groups |
4 |
|
tuberculosis - epidemiology - transmission |
4 |
|
uncertainty |
4 |
|
vaccine |
4 |
|
antibiotic use |
3 |
|
antimicrobial use/consumption |
3 |
|
asia-pacific |
3 |
|
asymptomatic |
3 |
|
avian influenza |
3 |
|
behaviour |
3 |
|
burden |
3 |
|
clinical severity |
3 |
|
communicable disease |
3 |
|
coxsackie |
3 |
|
delta |
3 |
|
ebola virus |
3 |
|
genetic susceptibility |
3 |
|
hfmd |
3 |
|
hospitalisation |
3 |
|
human infection |
3 |
|
human-to-human transmissibility |
3 |
|
implementation |
3 |
|
influenza a virus, h1n1 subtype - pathogenicity |
3 |
|
influenza, human - epidemiology |
3 |
|
key words influenza |
3 |
|
knowledge |
3 |
|
methicillin resistance |
3 |
|
mrsa |
3 |
|
omicron |
3 |
|
one health |
3 |
|
pandemics - statistics and numerical data |
3 |
|
policy implementation |
3 |
|
pre-symptomatic |
3 |
|
prudent antimicrobial prescription |
3 |
|
review |
3 |
|
sri lanka |
3 |
|
staphylococcus aureus |
3 |
|
symptomatic |
3 |
|
viral genomic load |
3 |
|
viral load |
3 |
|
virus a16 |
3 |
|
case fatality risk |
2 |
|
coronavirus infection |
2 |
|
hajj |
2 |
|
human |
2 |
|
influenza vaccine |
2 |
|
mental health |
2 |
|
middle east respiratory syndrome coronavirus |
2 |
|
novel coronavirus diseases 2019 |
2 |
|
severe acute respiratory syndrome coronavirus 2 |
2 |
|
subtropic |
2 |
|
temperate |
2 |
|
temperature |
2 |
|
test negative design |
2 |
|
tuberculosis - china - hong kong - prevention. |
2 |
|
vaccine effectiveness |
2 |
